{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:42:19Z","timestamp":1791902539248,"version":"4.3.4"},"reference-count":34,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cancer Control"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>We evaluated the clinical efficacy of primary Human Papillomavirus (HPV) testing and liquid-based cytology (LBC) for cervical screening in women below 30\u00a0years old.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective analysis of data collected prospectively from women 25\u00a0years or older who attended hospital-based gynaecology clinics for cervical screening. Simultaneous high-risk HPV testing with partial genotyping and LBC testing was performed. Comparison of clinical efficacy of HPV testing and LBC was performed for routine screening discharge rate, colposcopy referral rate, and number of colposcopies needed for each CIN2+ detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 6398 women included, 503 women (7.9%) tested positive for HPV DNA. The positivity was higher for 25-to-29 years old than for women \u226530\u00a0years old (12.6% vs 7.3%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001). The rate was markedly skewed by a low rate for women \u226545\u00a0years old. Similarly, more women below 30\u00a0years old (10.6%) had abnormal LBC results compared to women \u226530\u00a0years old (6.0%). Comparing LBC and HPV testing, the observed difference was not significant for discharge rate to interval screening (89.5% vs 87.4%). A higher referral to coloscopy rate (6.6 % vs 7.8%) was observed for HPV screening but the number of colposcopies for each detected CIN2+ (5 vs 7) was not significantly different. Clinical efficacy of HPV and LBC testing was similar in comparisons of women in 5-year groupings between 25 and 44\u00a0years old.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data indicated that cervical screening for women between 25 and 29\u00a0years old could adopt HPV screening as the older women.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10732748251336414","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T06:15:13Z","timestamp":1745475313000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Clinical Efficacy of Liquid-Based Cytology and High-Risk Human Papillomavirus Testing With Partial Genotyping in Cervical Screening of Women Below 30 Years Old"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9653-2794","authenticated-orcid":false,"given":"Joella Xiaohong","family":"Ang","sequence":"first","affiliation":[{"name":"Singapore General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Kuie","family":"Tay","sequence":"additional","affiliation":[{"name":"Singapore General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"e_1_3_7_2_2","unstructured":"World Health Organisation. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Accessed April 16 2025. https:\/\/iris.who.int\/bitstream\/handle\/10665\/336583\/9789240014107-eng.pdf."},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70360-2"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70156-1"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.47102\/annals-acadmedsg.V46N7p267"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70296-0"},{"key":"e_1_3_7_7_2","unstructured":"CervicalScreen Singapore. Management Guidelines for Cervical Screening & Preinvasive Disease of the Cervix. February 2019. Accessed April 16 2025. https:\/\/www.sccps.org\/wp-content\/uploads\/2019\/03\/CSS-Clinical-Mgt-Guidelines-2019_March-Release.pdf."},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2022.101813"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.09.006"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.10897"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0000000000000614"},{"key":"e_1_3_7_12_2","unstructured":"The American College of Obstetricians and Gynecologists (ACOG). Updated Cervical Cancer Screening Guidelines. 2021. Reaffirmed April 2024. Accessed April 16 2025. https:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2021\/04\/updated-cervical-cancer-screening-guidelines."},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21628"},{"key":"e_1_3_7_14_2","unstructured":"National Health System England.Topic 1: The NHS Cervical Screening Programme (NHSCSP). Updated 10 October 2024. Accessed April 16 2025. https:\/\/www.gov.uk\/government\/publications\/cervical-screening-cervical-sample-taker-training\/topic-1-the-nhs-cervical-screening-programme-nhs-csp."},{"key":"e_1_3_7_15_2","doi-asserted-by":"crossref","unstructured":"Regionala Cancercentrum. Livmoderhalscancer-prevention Nationellt v\u00e5rdprogram 2022-11-15 Version: 4.0. Accessed April 16 2025. https:\/\/kunskapsbanken.cancercentrum.se\/globalassets\/vara-uppdrag\/prevention-tidig-upptackt\/gynekologisk-cellprovskontroll\/vardprogram\/nationellt-vardprogram-cervixcancerprevention.pdf.","DOI":"10.1158\/1940-6207.CAPR-21-0086"},{"key":"e_1_3_7_16_2","volume-title":"Cervical cancer screening guidelines","author":"Cancer Council Australia","year":"2022","unstructured":"Cancer Council Australia. Cervical cancer screening guidelines. Sydney, NSW: Cancer Council Australia; 2022. https:\/\/www.cancer.org.au\/clinical-guidelines\/cervical-cancer\/cervical-cancer-screening. Accessed 3 June 2024."},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg037"},{"key":"e_1_3_7_18_2","unstructured":"Health Promotion Board - National Registry of Diseases Office. Singapore Cancer Registry Annual Report 2021. Accessed April 16 2025. https:\/\/www.nrdo.gov.sg\/docs\/librariesprovider3\/default-document-library\/scr-ar-2021-web-report.pdf."},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70731-8"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp367"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002388"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26194"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.11.076"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i3633"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g6223"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2016.06.005"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604324"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.8.813"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.11.075"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.47102\/annals-acadmedsg.2022471"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn065"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2006.01178.x"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-022-06409-3"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k499"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00524-2"}],"container-title":["Cancer Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748251336414","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10732748251336414","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748251336414","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:23:39Z","timestamp":1777386219000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10732748251336414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":34,"alternative-id":["10.1177\/10732748251336414"],"URL":"https:\/\/doi.org\/10.1177\/10732748251336414","relation":{},"ISSN":["1073-2748","1526-2359"],"issn-type":[{"value":"1073-2748","type":"print"},{"value":"1526-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"article-number":"10732748251336414"}}